CLAVAMOX 875mg/125mg amoxicillin (as trihydrate) 875 mg and clavulanic acid (as potassium) 125 mg tablet bottle pack

Country: অস্ট্রেলিয়া

ভাষা: ইংরেজি

সূত্র: Department of Health (Therapeutic Goods Administration)

সক্রিয় উপাদান:

amoxicillin trihydrate, Quantity: 1012.617 mg (Equivalent: amoxicillin, Qty 875 mg); potassium clavulanate, Quantity: 149.774 mg (Equivalent: clavulanic acid, Qty 125 mg)

থেকে পাওয়া:

Pharmacor Pty Ltd

INN (International Name):

amoxicillin trihydrate,potassium clavulanate

ফার্মাসিউটিকাল ফর্ম:

Tablet, film coated

রচনা:

Excipient Ingredients: dichloromethane; isopropyl alcohol; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type A; titanium dioxide; hypromellose; purified talc; diethyl phthalate; ethylcellulose

প্রশাসন রুট:

Oral

প্যাকেজ ইউনিট:

20 tablets

প্রেসক্রিপশন টাইপ:

(S4) Prescription Only Medicine

থেরাপিউটিক ইঙ্গিত:

CLAVAMOX Tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to Microbiology):,Urinary Tract Infections (uncomplicated and complicated), Lower Respiratory Tract Infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis, Upper Respiratory Tract Infections, such as sinusitis, otitis media and recurrent tonsillitis.Skin and Skin Structure Infection.,Appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to CLAVAMOX Tablets. However, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. Once these results are known, therapy should be adjusted if appropriate.,The treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to CLAVAMOX Tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

পণ্য সারাংশ:

Visual Identification: White to off white capsule shaped, biconvex, film coated tablets debossed with AM and CL separated by break line on one side and 1000 on other side.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

অনুমোদন অবস্থা:

Registered

অনুমোদন তারিখ:

2013-11-14

তথ্য লিফলেট

CLAVAMOX
Ver: 03
1
CLAVAMOX
(Amoxicillin & Clavulanic Acid)
CONSUMER MEDICINE INFORMATION (CMI)
WHAT IS IN THIS LEAFLET?
Please read this leaflet carefully
before
you
take CLAVAMOX
tablets.
This
leaflet
answers
some
common
questions
about
CLAVAMOX
tablets.
It
does
not contain all of the available
information.
It
does
not
take
the
place
of
talking
to
your
doctor
or
pharmacist.
All
medicines
have
risks
and
benefits. Sometimes ne risks are
found even when a medicine has
been used for many years. Your
doctor has weighed the expected
benefits
of
you
taking
CLAVAMOX tablets against the
risks this medicine could have
for you.
If you have any concerns about
taking this medicine, ask your
doctor or pharmacist.
Keep
this
leaflet
with
the
medicine.
You may need to read it again.
WHAT ARE CLAVAMOX
TABLETS USED FOR?
CLAVAMOX
tablets
contain
two active ingredients. One of
these
is
a
penicillin
called
amoxycillin
and
the
other
is
clavulanic
acid.
CLAVAMOX
tablets belong to the penicillin
group of antibiotics.
CLAVAMOX
tablets
are
used
for the short term treatment of
wide range of infections caused
by
bacteria.
These
infections
may
affect
the
chest
(e.g.
bronchitis
or
pneumonia),
bladder
(e.g.
cystitis),
sinuses
(e.g.
sinusitis),
the
ears
(e.g.
otitis media) or the skin.
CLAVAMOX
tablets
work
by
killing
the
bacteria
that
cause
these
infections.
CLAVAMOX
tablets
will
not
work
against
infections
caused
by
viruses
such as colds or the flu.
Your
doctor
may
have
prescribed it for another reason.
If
you
want
more
information
ask your doctor.
This medicine is available only
with a doctor’s prescription.
There is no evidence that it is
addictive.
BEFORE YOU TAKE
CLAVAMOX TABLETS
_DO NOT TAKE CLAVAMOX _
_TABLETS IF:_

you
have
had
an
allergic
reaction
to
penicillin
or
similar types of antibiotics
(such as cephalosporins) or
any
of
the
ingredients
contained in CLAVAMOX
tablets.
_The ingredients are _
_listed _
_at _
_the_
_end _
_of _
_this _
_leaflet. _
_Some _
_of _
_the _
_symptoms _
_of _
_an _
_allergic _
_reaction _
_may _
_inc

পণ্য বৈশিষ্ট্য

CLAVAMOX
Ver-04
1
AUSTRALIAN PRODUCT INFORMATION - CLAVAMOX 875MG/125MG
TABLETS (AMOXICILLIN AND POTASSIUM CLAVULANATE TABLETS)
1.
NAME OF THE MEDICINE
Amoxicillin trihydrate and Potassium clavulanate.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
CLAVAMOX 875MG/125MG TABLETS
is a combination product containing the semisynthetic
antibiotic, amoxicillin (as the trihydrate) and the β-lactamase
inhibitor, potassium clavulanate (as
the potassium salt of clavulanic acid).
For full list of excipients, see
SECTION 6.1- LIST OF EXCIPIENTS
3.
PHARMACEUTICAL FORM
CLAVAMOX 875 MG/125 MG TABLETS:
White to off white capsule shaped, biconvex, film
coated tablets debossed with
AM
and
CL
separated by breakline on one side and 1000 on other
side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
CLAVAMOX 875 mg/125 mg tablets
are indicated for short term treatment of bacterial
infections
at
the
following
sites
when
caused
by
sensitive
organisms
(see
SECTION
5.1
PHARMACODYNAMIC PROPERTIES, MICROBIOLOGY
):
Urinary Tract Infections (uncomplicated and complicated)
Lower Respiratory Tract Infections, including community acquired
pneumonia and acute
exacerbations of chronic bronchitis
Upper Respiratory Tract Infections, such as sinusitis, otitis media
and recurrent tonsillitis.
Skin and Skin Structure Infection.
Appropriate culture and susceptibility studies should be performed to
identify the causative
organism(s) and determine its (their) susceptibility to amoxicillin
and potassium clavulanate
CLAVAMOX
Ver-04
2
tablets. However, when there is reason to believe an infection may
involve any of the β-
lactamase producing organisms listed above, therapy may be instituted
prior to obtaining the
results from bacteriological and susceptibility studies. Once these
results are known, therapy
should be adjusted if appropriate.
The treatment of mixed infections caused by amoxicillin susceptible
organisms and β-lactamase
producing organisms susceptible to amoxicillin and potassium
clavulanate tablets should not
require the addition of another